EnabledFuture | Risk Intelligence | Pharmaceutical Supply Chains & Competition
BASF–Evonik Merger Part 1: The pharmaceutical supply choice a takeover would erase
A BASF–Evonik merger or takeover has become a serious prospect. The impacts of such a transaction would have ripple effects across the global chemical industry. In this series of articles, EnabledFuture will examine those impacts and what they might mean for our market sectors and clients. Both companies produce and use catalyst materials, including in fine and speciality chemical production.
In subsequent articles, we will look at how a BASF–Evonik merger could exploit the companies’ synergies for a stronger energy-transition play. This article is a risk intelligence exercise, examining the potential negative supply-chain fallout if two major European pharmaceutical coating-polymer producers consolidate their operations, product lines and pricing strategies.
The pharmaceutical-polymer overlap may not, on its own, be sufficient to justify regulatory intervention under competition law, but it does raise uncomfortable questions about the implications of giant chemical companies’ market power for sustainability and innovation. Our analysis also aims to offer Evonik, currently an unwilling target, insights into negotiating a fair price.
Our reading of BASF’s public approach suggests some urgency, and we see considerable strategic value to BASF in Evonik’s pharmaceutical coating-polymer assets. EnabledFuture’s negotiating position is that Evonik should seek a price floor of €30 (thirty euros) per share.
Risk Intelligence Insight: In 2016, BASF introduced a pharmaceutical coating polymer as an alternative source of supply. In 2026, its proposed acquisition of Evonik would bring that product and the rival it was designed to challenge under common ownership. That is a concrete loss of independent competition—not a hypothetical patent overlap.
EnabledFuture's finding. BASF and Evonik currently market directly competing grades of methacrylic acid–ethyl acrylate enteric-coating polymer, both in dry-powder and aqueous-dispersion form. BASF itself names the Evonik products as equivalents. A BASF–Evonik merger would eliminate the independent commercial decisions behind those rival ranges. Other independently controlled suppliers exist, including two manufacturers with publicly documented access to European customers; therefore the issue is loss of an established competitive alternative, not the creation of a demonstrated monopoly.
The independence BASF once sold as a benefit
On 4 April 2016, BASF introduced Kollicoat MAE 100-55 for pharmaceutical enteric coatings. Its selling proposition included direct substitution for comparable materials and greater supply flexibility. BASF explicitly described the benefit to pharmaceutical manufacturers as “more flexibility and supply security.”
Seven years later, BASF's own technical presentation, page 16, identified precisely which Evonik grades its products matched.
| BASF product | Evonik rival | Competition actually established |
|---|---|---|
| Kollicoat MAE 100-55 | EUDRAGIT L 100-55 | Two independently marketed, chemically equivalent Type A enteric-polymer powders. |
| Kollicoat MAE 30 DP | EUDRAGIT L 30 D-55 | Two independently marketed 30% aqueous-dispersion options for pH-dependent enteric coating. |
Both pairs serve the same fundamental purpose: protecting a dosage form in gastric conditions and enabling release above approximately pH 5.5. The products are not necessarily identical in every formulation. Their competitive relationship, however, is not disputed by BASF's marketing. Evonik's EUDRAGIT product record confirms its matching powder grade and pharmacopoeial positioning.
Independent researchers also purchased the two powder products from BASF and Evonik and compared them in a 2024 peer-reviewed study. The experiment used developmental drug-delivery foils rather than commercial tablets, so it cannot certify interchangeability in every medicine. It nevertheless reinforces that the named products are practical technical alternatives, not merely adjacent chemical technologies.
A combined BASF–Evonik group could retain both factories and both brand names while removing the competition between their owners. That is the change which matters to customers.
Why pharmaceutical manufacturers have an interest in that independence
Enteric polymers determine when a medicine releases its active ingredient. Their significance is demonstrable in approved products: the European Medicines Agency's product information for Vumerity, for example, identifies methacrylic acid–ethyl acrylate copolymer (1:1), Type A, among the capsule ingredients. The public record identifies the chemistry, not which polymer brand the manufacturer purchases.
For a medicine manufacturer, a second independent supplier is not simply another item in a catalogue. It provides a separate counterparty for price negotiation, a separate investment and production decision, and potentially an alternative during disruption. That value is especially relevant where a formulation has been established around a particular excipient and a supplier change involves technical and quality work.
The EU's 2015 excipient GMP risk-assessment guidelines require manufacturers to assess the source, use and quality arrangements of excipients. The revised EU Variations Regulation has applied since 1 January 2025; the updated Variations Guidelines apply from 15 January 2026. This framework governs changes to approved medicinal-product particulars where relevant. Consequently, possession of the same pharmacopoeial identity does not, by itself, mean that an unqualified replacement can be introduced immediately into every marketed formulation.
The merger would therefore remove one independent source of commercial pressure at the same point in the supply chain where rapid supplier substitution may require product-specific qualification. It would not automatically interrupt supply or require manufacturers to reformulate their medicines.
Are there other genuinely independent suppliers? Yes.
EnabledFuture identified competing polymer products from Vikram Thermo and Ideal Cures, both based in India. These are not just alternative coating brands: both companies market the matching polymer chemistry in powder and dispersion forms and have publicly identifiable routes to European customers.
| Independent manufacturer | Relevant polymer products | Published evidence relevant to European supply |
|---|---|---|
| BASF | Kollicoat MAE 100-55; MAE 30 DP | German producer; commercial launch and supply-security proposition. |
| Evonik | EUDRAGIT L 100-55; L 30 D-55 | German producer; pharmaceutical grade and compendial claims. |
| Vikram Thermo | DRUGCOAT L100-55; L30D | Manufacturer lists both forms; Germany-based HARKE Pharma markets DRUGCOAT as distributor. |
| Ideal Cures | ECOPOL L 100 55; L 30 D 55 | Commercial Type A powder and 30% dispersion; IPDistribution in Italy markets ECOPOL, and the manufacturer's CPHI listing names EU countries among sales markets. |
A register of four directly documented manufacturer portfolios, not a census of all manufacturers or a calculation of EU market shares. Their presence establishes potential alternatives; it does not mean all four are qualified in every customer formulation.
Within these four documented manufacturer portfolios, the proposed acquisition would change the ownership structure from four independent business groups to three: a combined BASF–Evonik group, Vikram Thermo and Ideal Cures. The continuing presence of those independent competitors is relevant evidence against a monopoly narrative. Their European channels are real, but their ability to replace BASF or Evonik in particular approved formulations is a distinct commercial question.
Nor should finished-coating suppliers be double-counted as polymer producers. Evonik's 2013 agreement with Colorcon identified Evonik's EUDRAGIT L 100-55 as the key polymer ingredient in Colorcon's Acryl-EZE system. Other companies, including JRS Pharma and Bestpharma, market finished systems using the same polymer chemistry; that does not itself establish independent manufacture of the underlying copolymer.
Why this belongs in merger control
The European Commission's Horizontal Merger Guidelines, paragraph 28, directly address the loss of rivalry between close substitutes. They do not make monopoly creation a prerequisite for competition concerns. A finding of material harm would still require evidence about how customers choose suppliers and how effectively remaining firms constrain the merged company.
In this case, the first test has effectively been answered by the merging parties' own public material: the products are marketed head-to-head in two closely comparable forms, and BASF entered the market with supply choice as part of its stated proposition. The next regulatory test is sharply defined: whether the existing alternative producers offer enough competitive constraint to replace the lost BASF–Evonik rivalry for pharmaceutical customers in the European Economic Area.
This can be examined with existing business records: tender and win/loss histories, customers that source or have qualified both companies, sales by polymer grade, delivery performance, and the commercial ability of independent suppliers to serve those customers. It does not require treating every chemically similar coating system as an independent polymer manufacturer.
If that evidence shows material harm, any remedy should preserve a viable, independently controlled polymer supply business, including manufacturing, quality assurance, technical support and customer relationships. Simply preserving the Kollicoat and EUDRAGIT brand names within the same corporate group would not preserve the rivalry between their owners.
EnabledFuture assessment
This pharmaceutical-polymer overlap warrants treatment as a specific horizontal competition issue within any examination of BASF's proposed takeover of Evonik. The evidence is stronger than a generic assertion that two chemical groups have similar patents: BASF has identified the rival products, publicly stated its supply-independence rationale, and maintained directly comparable pharmaceutical grades.
Other manufacturers with EU-facing commercial routes mean that the market is not without alternatives. They do not undo the fact that a transaction would remove an established, independently controlled competitor. The relevant merger-control task is to determine whether the remaining alternatives are effective for actual pharmaceutical customers—and, if not, to preserve an independent competitor through a proportionate remedy.
Supply security is not measured by the number of product labels left on a website. It depends in part on how many suppliers can make independent decisions when a manufacturer needs them to.
15 additional product-level or technology-level competition cases
EnabledFuture has identified 15 further examples of competing products or technical solutions across BASF and Evonik, in addition to the Kollicoat–EUDRAGIT pharmaceutical enteric-polymer case. The significance lies in the cumulative transfer of independent commercial and technological decisions—not in the number 15 as such. Each example represents a product-level screening candidate; these are not 15 established antitrust markets or proven infringements.
The cases span eight chemically identical or closely related product groups, four coatings-additive functions, and three competing technologies or material routes. Importantly, the proposed disposal of Evonik’s Oxeno business makes the plasticiser examples contingent on which assets would actually be acquired.
A. Eight direct or closely related chemical-product cases
| A. Direct and closely related chemical products |
|---|
Case 1 BASF: Baxxodur EC 201 Evonik: VESTAMIN IPD Documented relationship: Isophorone diamine (IPD), CAS 2855-13-2; epoxy curing agents for coatings, adhesives and composites. |
Case 2 BASF: Lupragen N201 Evonik: DABCO 33 LV Documented relationship: Triethylenediamine (TEDA) in dipropylene glycol; polyurethane gel catalysis. |
Case 3 BASF: Hexamoll DINCH Evonik: ELATUR CH Documented relationship: Diisononyl cyclohexane-1,2-dicarboxylate (DINCH); PVC plasticisers used in sensitive applications. |
Case 4 BASF: Palatinol N Evonik: VESTINOL 9 Documented relationship: Diisononyl phthalate (DINP); general-purpose PVC plasticiser. |
Case 5 BASF: Basonat HI 100 NG Evonik: VESTANAT HT 2500/100 Documented relationship: HDI-isocyanurate crosslinkers for two-component polyurethane coatings; similar chemistry, with grade-specific differences. Merger significance and sources: Competing crosslinker products may offer independent qualification and technical-service options. (BASF selection guide · Evonik technical range) |
Case 6 BASF: Cetiol J 600 Evonik: TEGOSOFT OER MB Documented relationship: Oleyl erucate, INCI identity; cosmetic emollient and sensory ingredient. Merger significance and sources: Same INCI name suggests product comparability; process, certification and grade differences still affect actual switching. (BASF technical data · Evonik) |
Case 7 BASF: Myritol 318 Evonik: TEGOSOFT CT MB Documented relationship: Caprylic/capric triglyceride, INCI identity; cosmetic emollient and solvent. |
Case 8 BASF: Dehyton PK 45 Evonik: TEGO Betain F 50 Documented relationship: Cocamidopropyl betaine, INCI identity; mild amphoteric surfactant. |
Interpretation. The first group establishes multiple instances of independent suppliers offering the same chemical or closely competing grades. That is stronger than describing the companies as active in the same sector. It is not, however, evidence that each product is scarce or that customers lack alternatives. The Oxeno cases should be excluded from any combined-capacity calculation if the divestment completes before a BASF transaction.
B. Four overlapping coatings-additive functions
| B. Coatings-additive functions |
|---|
Case 9 BASF family: Efka PX / Dispex Ultra Evonik family: TEGO Dispers Competing function: Pigment wetting, dispersion and stabilisation in paint and ink systems. |
Case 10 BASF family: FoamStar Evonik family: TEGO Foamex Competing function: Defoaming, micro-foam elimination and coating surface quality. |
Case 11 BASF family: Hydropalat Evonik family: TEGO Wet Competing function: Substrate wetting, surface-tension reduction, levelling and defect control. |
Case 12 BASF family: Rheovis Evonik family: TEGO Viscoplus Competing function: Rheology modification and viscosity management in coating formulations. |
These four functions are not interchangeable with each other. A competition assessment would need to distinguish the relevant additive classes and application-specific substitution. The commercial issue is cumulative: common ownership could reduce the number of independent suppliers to the same coatings customers across several formulation steps, with implications for price negotiations, technical support and R&D competition.
C. Three competing technology or material routes
| C. Competing technology and material routes |
|---|
Case 13 BASF route: Ultramid Flex F40L Evonik route: VESTAMID PA12 Technical relationship: BASF documents F40L as a PA12 replacement in demanding hose applications; Evonik supplies PA12 for automotive fluid and air lines. Current production or shipment of the specific BASF F40L grade has not been independently verified. |
Case 14 BASF route: BASF–Dow HPPO Evonik route: Evonik–thyssenkrupp Uhde HPPO Technical relationship: Competing independently developed hydrogen-peroxide-to-propylene-oxide process platforms. Merger significance and sources: Technology licensing, catalyst know-how and retained rights of Dow and Uhde matter; the technologies are not wholly owned by BASF and Evonik. (BASF–Dow process · Evonik technology) |
Case 15 BASF route: OASE green Evonik route: SEPURAN Green Technical relationship: Chemical solvent absorption versus hollow-fibre membranes for biogas upgrading. Merger significance and sources: Competing routes for some biomethane investments; integration could influence choice of technology but they may not share a single antitrust market. Evonik’s October 2026 transfer of SEPURAN sales operations in Japan to Evonik Japan was an internal sales-channel change, not a divestment of the membrane technology (Daicel-Evonik notice). (BASF · Evonik) |
Finding: Including the separately documented Kollicoat–EUDRAGIT case, EnabledFuture has identified 16 product or technology competition-screening examples. They are not automatically 16 independent markets: some belong to overlapping product families, some are contingent on disposals, and some concern different technologies competing for the same project. The finding is nevertheless sufficient to challenge a merger narrative based solely on complementary portfolios.
Precedents: when specialist overlaps changed actual transactions
Previous merger decisions show that regulators can require the sale of production businesses, associated intellectual property and research capacity—not merely promises to maintain competitive prices. The relevant precedent is a business-wide remedy rather than one concession for each product name.
| Transaction | What happened | Implication for BASF–Evonik | Primary sources |
|---|---|---|---|
| BASF / Solvay polyamides (2019) | EU conditional approval required European manufacturing assets and innovation capability to be divested. | Industrial integration and upstream-input advantages did not displace competition concerns; BASF itself encountered this constraint. | (BASF announcement) |
| Sika / MBCC (2022–23) | The CMA required divestment of major chemical-admixtures activities; the purchaser was scrutinised and Cinven ultimately acquired the assets. | Multiple specialist formulations and R&D capabilities can form a remedy package large enough to change deal economics. | (CMA case · Sika sale) |
| Dow / DuPont (2017) | Commitments included crop-protection businesses and R&D, as well as Dow’s ethylene-acrylic-acid copolymer and ionomer assets. | The competitive asset being lost may be a discovery organisation or future technology rather than only installed capacity. | (EU notice) |
| Bayer / Monsanto (2018) | The Commission accepted a remedy package worth more than €6bn, including assets intended to preserve independent innovation and competition. | Competition remedies can absorb a substantial part of the industrial value targeted by the buyer. | (European Commission) |
| Evonik / PeroxyChem (2020) | The US FTC challenged the acquisition in hydrogen peroxide; the attempt to obtain a preliminary injunction was unsuccessful and the deal proceeded. | A necessary counterexample: superficially narrow product definitions still require robust evidence of real competition and geography. | (FTC case) |
Collectively, these precedents support a material proposition: the takeover could be cleared only after divestments that reduce the value of the combination to BASF. They do not determine that outcome in advance. The decisive issue is whether the proposed combination would significantly impede effective competition in one or more properly defined markets. EU Horizontal Merger Guidelines.
The acquisition economics: what BASF could actually be buying
A conventional takeover premium starts with Evonik’s share price. A serious assessment should also calculate what controlling Evonik is worth specifically to BASF, and what BASF could achieve by acquiring individual businesses instead. The relevant possibilities are recurring industrial efficiencies, ownership of differentiated technology and customers, and the option to divest assets or reorganise production. These must be valued separately to avoid counting the same cash flow more than once.
| Potential source of value | What an acquisition might provide | Constraint that affects value |
|---|---|---|
| Retained specialty businesses | Continuing revenue, EBITDA and future cash flow from differentiated products. | Standalone value is not itself a synergy; the acquisition price already pays for these earnings. |
| Cost synergies | Procurement, logistics, utilities, overhead and site-operation savings. | Evonik is already restructuring; announced efficiencies cannot be counted twice. Integration costs and employment commitments must be deducted. |
| Manufacturing reconfiguration | Capacity consolidation, feedstock routing and higher utilisation at preferred plants. | Closures may create stranded assets, remediation costs, loss of customers and political or contractual restrictions. |
| Asset disposals | Proceeds from divesting businesses or site infrastructure. | Sale proceeds replace future earnings; a disposal is not an additional permanent cash-flow stream. |
| Technology and IP | Access to specialist catalysts, process packages, protected know-how and technical teams. | Joint ownership, licensing obligations and possible competition remedies can limit control. |
| Market structure | Changed bargaining positions against suppliers, distributors and customers. | Foreclosure or the elimination of substantial independent competition may trigger antitrust remedies. |
BASF’s published statements argue for industrial integration and international competitiveness. Those statements are evidence of BASF’s expressed rationale, not proof of how it would allocate assets after completion. Conversely, a breakup or aggressive cost-extraction scenario is commercially testable but is not an established intention of BASF. BASF’s public takeover position.
A useful valuation discipline
| Component | Treatment in a buyer-specific valuation |
|---|---|
| Evonik standalone equity value | Use independently forecast free cash flow, debt, pensions, contingent liabilities and capital needs. |
| Incremental BASF-only synergies | Include only additional net cash flows that arise because BASF, rather than another owner, controls Evonik. |
| Disposal option value | Model net proceeds less the cash flows surrendered, separation costs and tax consequences. |
| Merger-control remedies | Deduct potential loss of assets, innovation capabilities and associated synergies. |
| Transaction costs and financing | Deduct acquisition funding costs, restructuring cash outflows and additional risk. |
BASF’s balance sheet and product-liability exposure: relevant, not proof of motive
A further due-diligence question is whether Evonik’s potential earnings and asset value would be especially attractive in light of BASF’s existing capital commitments and contingent liabilities. This is a reasonable financial scenario to model, but there is no published evidence establishing that anticipated lawsuits are the reason BASF wants Evonik.
| Published measure | Reported amount or position | Interpretation |
|---|---|---|
| BASF operating cash flow, Jan–Sep 2026 | €823 million | Cash conversion was materially weaker than reported adjusted EBITDA over the same period. |
| BASF free cash flow, Jan–Sep 2026 | −€1.040 billion | A funding constraint to test, not proof of distress. |
| BASF net debt, 30 September 2026 | €16.652 billion | Lower than €20.891 billion one year earlier; the reduction must also be recognised. |
| BASF PFAS lawsuits, February 2026 | More than 8,700 lawsuits naming group companies | Claims remain contested; case count is not a damages estimate. |
| BASF AFFF-related US water-system settlement | $316.5 million (€305 million) | Paid: $4 million in administration costs in July 2024 and $312.5 million in settlement claims in March 2025. No admission of liability; other claims remain. |
Sources: BASF Q3 2026 financial data and BASF 2025 report, litigation note. BASF attributes much of its AFFF-related PFAS litigation exposure to its legal succession to Ciba; it states that adverse results could be financially material. These disclosures justify a contingent-liability scenario, not an allegation of impending insolvency or a concealed takeover motive.
In particular, acquiring Evonik would not extinguish BASF’s existing liabilities. It could increase group cash-generating capacity, but it would also require financing a significant acquisition and potentially accepting Evonik’s own liabilities. A sound model must cover both sides.
What this means for Evonik’s negotiating position
The 16 documented cases and merger precedents give Evonik something more useful than a list of objections: a structured way to interrogate how BASF expects to create value from the whole company, what parts of that value might be lost to remedies, and why ownership of all Evonik businesses would be preferable to selective asset acquisitions.
Evonik’s board rejected BASF’s improved, non-binding approach on 30 October 2026 and reaffirmed its independent strategy. On 3 November, Evonik reported third-quarter adjusted EBITDA of €629 million, up 40% year on year, and guided to the upper half of its €2.0–€2.2 billion 2026 range. Those are concrete facts supporting an independent valuation case. Evonik board statement; Evonik Q3 results.
The €30-per-share negotiating scenario
The reported BASF approach of €24 per share implies approximately €11.18 billion in equity consideration. At €30 per share, using the same implied share count, the price would be approximately €14.0 billion—about €2.8 billion more, or a 25% increase. These are comparison figures, not a fairness opinion or a determination that €30 is sufficient. Reuters report of €24 approach.
EnabledFuture’s position: Evonik should not negotiate a price solely by applying a premium to its unaffected share price. The economically relevant test is the standalone value available to its shareholders, plus a justified share of the incremental value BASF could realise from control. A higher buyer-specific valuation cannot be inferred from the 16 examples alone; it must be modelled from the associated businesses, cash flows and remedies.
Five actions consistent with a lawful, credible defence
- Publish a defensible independent value proposition. Set out the cash generation, technology pipeline and strategic alternatives that shareholders would retain if BASF walks away.
- Build a confidential product-market and remedy map. Connect each direct overlap to the relevant sales, customers, capacity and R&D assets, without treating the count of brands as the count of markets.
- Quantify a buyer-specific value bridge. Separate industrial synergies, disposals, restructuring costs, lost earnings and competition remedies.
- Engage major shareholders on economics, not rhetoric. RAG-Stiftung’s substantial position matters; its interests must be addressed through a credible long-term valuation rather than assuming endorsement of a particular price.
- Use antitrust evidence for its proper purpose. Provide factual competition concerns to competent authorities; do not use allegations of wrongdoing or threats of regulatory complaints as bargaining instruments.
Employment commitments also affect the model. BASF has publicly stated it would preserve Evonik’s existing agreements excluding compulsory redundancies until 2032. That constrains, but does not eliminate, potential restructuring; voluntary departures, business sales and commercial reorganisation must be evaluated against their actual legal and economic costs. BASF statement.
Conclusion: the value of independence is now a measurable transaction issue
The additional cases establish a repeated pattern of competing products and technologies across the two portfolios. The precedents establish that competition authorities have previously required substantial disposals of manufacturing and innovation assets in analogous chemical transactions—including acquisitions involving BASF itself. The financial analysis establishes why Evonik should ask what the whole portfolio is worth to BASF, rather than merely whether its approach looks generous relative to a trading price.
The central board-level question is therefore what BASF gains by owning Evonik in its entirety that it cannot obtain through commercial agreements, joint ventures or individual asset purchases—and how much of that gain would survive competition remedies?
Until that is answered, the prudent starting position for Evonik is a credible, investable independent strategy and a buyer-specific valuation. If BASF walks away, Evonik continues to own the earnings streams, technologies, people and commercial options that BASF has sought to acquire. Whether a €30-per-share offer would compensate shareholders adequately must be demonstrated by valuation, not asserted by negotiating instinct.
Publication note (4 November 2026). Sources are embedded next to the relevant statements. The 15 examples are a documented screening set, not final EU market definitions or a forecast of any competition-authority decision. Financial exposure and the acquirer’s intentions are distinguished from assumptions and scenarios.